#1 Clinical Trials Search in Europe

Natalizumab

This article explores the use of Natalizumab (also known as Tysabri) in clinical trials for the treatment of multiple sclerosis (MS). Natalizumab is being studied in various forms of MS, including relapsing-remitting, primary progressive, and secondary progressive types. The trials aim to evaluate the drug’s safety, efficacy, and optimal dosing strategies. Some studies are also investigating Natalizumab’s potential in treating other conditions like pulmonary metastatic osteosarcoma.

Table of Contents

What is Natalizumab?

Natalizumab, also known by its brand name Tysabri or research code BG00002, is a medication primarily used to treat certain forms of multiple sclerosis (MS)[1][6]. It belongs to a class of drugs called monoclonal antibodies, which are laboratory-produced molecules designed to serve as substitute antibodies that can restore, enhance, or mimic the immune system’s attack on specific cells[5].

Conditions Treated by Natalizumab

Natalizumab is primarily used to treat the following conditions:

  • Relapsing-Remitting Multiple Sclerosis (RRMS): This is the most common form of MS, characterized by periods of symptom flare-ups followed by periods of remission[1].
  • Primary Progressive Multiple Sclerosis (PPMS): A less common form of MS where symptoms steadily worsen over time without distinct relapses or remissions[8].
  • Secondary Progressive Multiple Sclerosis (SPMS): A form of MS that develops in some people with RRMS, where the disease begins to progress more steadily[8].
  • Crohn’s Disease: While not the primary focus of the provided trials, Natalizumab is also approved for treating moderately to severely active Crohn’s disease in adult patients who have had an inadequate response to, or are unable to tolerate, conventional therapies[2].

How Natalizumab Works

Natalizumab works by targeting a specific protein on the surface of immune cells called alpha-4 integrin. By binding to this protein, Natalizumab prevents these immune cells from entering the brain and spinal cord, where they would otherwise cause inflammation and damage to the protective covering of nerve fibers (myelin)[6].

This mechanism of action is measured through what’s called “alpha-4 integrin saturation.” Higher levels of saturation indicate that more of the target proteins are bound by Natalizumab, potentially leading to greater effectiveness of the drug[10].

How Natalizumab is Administered

Natalizumab is typically administered in one of two ways:

  • Intravenous (IV) infusion: The most common method, where the drug is given directly into a vein. The standard dose is 300 mg every 4 weeks[1].
  • Subcutaneous (SC) injection: A newer method being studied, where the drug is injected just under the skin. This method is also typically given as 300 mg every 4 weeks[10].

Some studies are exploring extended interval dosing, where the time between doses is increased to 6 or even 8 weeks, guided by the concentration of the drug in the patient’s blood[9].

Efficacy of Natalizumab

Natalizumab has shown significant efficacy in treating multiple sclerosis. Its effects are measured through various outcomes, including:

  • Reduction in relapses: Natalizumab has been shown to reduce the frequency of MS relapses[1].
  • Slowing disease progression: It can help slow the worsening of disability in MS patients[1].
  • Reduction in brain lesions: Natalizumab has been shown to reduce the number of new or enlarging brain lesions visible on MRI scans[10].

Safety and Side Effects

While Natalizumab is generally well-tolerated, it does come with potential side effects and risks:

  • Progressive Multifocal Leukoencephalopathy (PML): This is a rare but serious brain infection that has been associated with Natalizumab use. Patients are typically monitored closely for signs of PML[4].
  • Infusion reactions: Some patients may experience reactions during or shortly after receiving an infusion of Natalizumab[5].
  • Liver problems: In some cases, Natalizumab may affect liver function[2].
  • Infections: Because Natalizumab affects the immune system, it may increase the risk of certain infections[1].

Patients are typically monitored closely while on Natalizumab, with regular blood tests and MRI scans to check for any adverse effects or signs of disease progression[1].

Ongoing Research and Future Directions

Research on Natalizumab is ongoing, with several areas of focus:

  • Extended interval dosing: Studies are exploring whether some patients can safely receive Natalizumab less frequently, potentially reducing risks while maintaining efficacy[9].
  • Subcutaneous administration: Research is being conducted on the effectiveness and patient preference for subcutaneous injections versus intravenous infusions[10].
  • Combination therapies: Some studies are looking at combining Natalizumab with other MS treatments to potentially enhance effectiveness[7].
  • Use in progressive forms of MS: While primarily used for relapsing forms of MS, research is ongoing into its potential benefits for progressive forms of the disease[8].
  • Treatment of other conditions: In addition to MS and Crohn’s disease, researchers are exploring the potential use of Natalizumab in other conditions, such as certain types of cancer[2].
Aspect Details
Drug Name Natalizumab (Tysabri)
Primary Conditions Studied Multiple Sclerosis (Relapsing-Remitting, Primary Progressive, Secondary Progressive)
Other Conditions Pulmonary Metastatic Osteosarcoma
Administration Methods Intravenous (IV) infusion, Subcutaneous (SC) injection
Dosing Strategies Standard Interval Dosing (SID), Extended Interval Dosing (EID)
Common Outcome Measures MRI lesions, Relapse rates, Disability progression, Quality of life
Safety Monitoring PML risk, Anti-Natalizumab Antibodies, Adverse events
Biomarkers Studied CSF osteopontin, Neurofilament heavy chain, Myelin basic protein
Combination Therapies Natalizumab with Glatiramer Acetate
Personalized Medicine Approaches Dose interval adjustments based on serum concentrations

FAQ

  • What is Natalizumab? Natalizumab, also known by the brand name Tysabri, is a medication used to treat relapsing forms of multiple sclerosis (MS). It works by preventing certain immune cells from entering the brain and spinal cord, which can reduce inflammation and damage associated with MS.
  • How is Natalizumab administered in clinical trials? In most trials, Natalizumab is administered as an intravenous (IV) infusion, typically at a dose of 300 mg every 4 weeks. Some studies are also exploring subcutaneous (SC) injections and extended interval dosing (EID) schedules, such as every 6 weeks.
  • What are the main objectives of Natalizumab clinical trials? The main objectives include assessing the safety and efficacy of Natalizumab in various forms of MS, evaluating its effects on disease progression, exploring optimal dosing strategies, and investigating its potential in treating other conditions like pulmonary metastatic osteosarcoma.
  • What are some common outcome measures used in Natalizumab trials? Common outcome measures include the number of new or enlarging brain lesions on MRI scans, relapse rates, changes in disability scores (such as EDSS), quality of life assessments, and various biomarkers in blood and cerebrospinal fluid.
  • Are there any safety concerns associated with Natalizumab use? Yes, one of the main safety concerns is the risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection. Many trials monitor patients for PML and other adverse events, as well as the development of anti-natalizumab antibodies.

Ongoing Clinical Trials on Natalizumab

  • Study on the Effectiveness of Autologous Stem Cell Transplantation with Cytarabine in Patients with Aggressive Multiple Sclerosis

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Personalized Dosing of Natalizumab for Patients with Relapsing-Remitting Multiple Sclerosis

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Safety of Tenofovir Alafenamide and Natalizumab for People with Multiple Sclerosis

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Norway

  • Study on Metformin for Delaying Progression in Non-Active Progressive Multiple Sclerosis Patients

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

Glossary

  • Relapsing-Remitting Multiple Sclerosis (RRMS): The most common form of MS characterized by clearly defined attacks of new or increasing neurologic symptoms followed by periods of partial or complete recovery.
  • Progressive Multifocal Leukoencephalopathy (PML): A rare but serious brain infection caused by the John Cunningham (JC) virus, which can occur in some patients taking Natalizumab.
  • Expanded Disability Status Scale (EDSS): A method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time. The scale ranges from 0 to 10 in 0.5 unit increments.
  • Gadolinium-enhancing lesions: Areas of active inflammation in the brain or spinal cord that can be seen on MRI scans after the injection of a contrast agent called gadolinium.
  • Anti-Natalizumab Antibodies (ANAs): Antibodies that the body may produce against Natalizumab, which can potentially reduce the drug's effectiveness or cause allergic reactions.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body over time.
  • Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs on the body, including their mechanisms of action and the relationship between drug concentration and effect.
  • Extended Interval Dosing (EID): A dosing strategy where the time between drug administrations is increased, such as giving Natalizumab every 6 weeks instead of every 4 weeks.
  • Cerebrospinal Fluid (CSF): The clear, colorless fluid that surrounds the brain and spinal cord, often analyzed in MS studies to measure various biomarkers of disease activity.
  • Magnetic Resonance Imaging (MRI): A non-invasive imaging technique used to visualize the brain and spinal cord, commonly used in MS to detect and monitor lesions and disease progression.

References

  1. https://clinicaltrials.gov/study/NCT03689972
  2. https://clinicaltrials.gov/study/NCT03811886
  3. https://clinicaltrials.gov/study/NCT04832399
  4. https://clinicaltrials.gov/study/NCT04964700
  5. https://clinicaltrials.gov/study/NCT05925049
  6. https://clinicaltrials.gov/study/NCT00744679
  7. https://clinicaltrials.gov/study/NCT00097760
  8. https://clinicaltrials.gov/study/NCT01077466
  9. https://clinicaltrials.gov/study/NCT03516526
  10. https://clinicaltrials.gov/study/NCT05532163